Successful Alternate-day Osimertinib Administration with Desensitization Following Osimertinib-induced Hepatotoxicity and Neutropenia in a Case of EGFR-mutant Lung Cancer
Abstract
Osimertinib is widely used in cases of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) gene mutations, including Thr790 Met mutations. We herein report a case of successful desensitization therapy combined with alternate-day dosing after osimertinib-induced hepatotoxicity and neutropenia. A 67-year-old woman with recurrent EGFR-mutated NSCLC after surgery discontinued osimertinib due to hepatotoxicity. Following disease progression and detection of the Thr790 Met mutation after afatinib treatment, desensitization therapy with osimertinib was initiated at 0.1 mg/day. Grade 3 neutropenia developed during dose escalation. However, alternate-day dosing enabled continuation and escalation to the standard dose. Alternate-day dosing may mitigate adverse events during dose escalation.
Related
- Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study
- Preventive Effect of Angiotensin II Receptor Blockers on High-Dose Methotrexate-Induced Hepatotoxicity Determined Using a Hospital-Based Database Analysis
- Partial agonists and heteromeric Kainate receptor desensitization
- Eye movement desensitization and reprocessing in trauma related panic disorder: clinical outcomes through a neuroendocrine lens.
- High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)
BibTeX
@article{furuya2026successful,
title = {{Successful Alternate-day Osimertinib Administration with Desensitization Following Osimertinib-induced Hepatotoxicity and Neutropenia in a Case of EGFR-mutant Lung Cancer}},
author = {Tatsuo Furuya and Satoru Okada and Masanori Shimomura and Shinsaku Tokuda and Masayoshi Inoue},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.7611-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7611-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Successful Alternate-day Osimertinib Administration with Desensitization Following Osimertinib-induced Hepatotoxicity and Neutropenia in a Case of EGFR-mutant Lung Cancer
AU - Tatsuo Furuya
AU - Satoru Okada
AU - Masanori Shimomura
AU - Shinsaku Tokuda
AU - Masayoshi Inoue
PY - 2026
DA - 2026/07/04
JO - Internal Medicine
DO - 10.2169/internalmedicine.7611-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7611-26/_article
AB - Osimertinib is widely used in cases of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) gene mutations, including Thr790 Met mutations. We herein report a case of successful desensitization therapy combined with alternate-day dosing after osimertinib-induced hepatotoxicity and neutropenia. A 67-year-old woman with recurrent EGFR-mutated NSCLC after surgery discontinued osimertinib due to hepatotoxicity. Following disease progression and detection of the Thr790 Met mutation after afatinib treatment, desensitization therapy with osimertinib was initiated at 0.1 mg/day. Grade 3 neutropenia developed during dose escalation. However, alternate-day dosing enabled continuation and escalation to the standard dose. Alternate-day dosing may mitigate adverse events during dose escalation.
SN - 1349-7235
SN - 0918-2918
ER -